<DOC>
	<DOCNO>NCT00193570</DOCNO>
	<brief_summary>This phase I study characterize safety , tolerability , maximum tolerate dose dose-limiting toxicity weekly bolus Topotecan administer combination different dose regimen docetaxel . We also evaluate anti-tumor activity combination regimen .</brief_summary>
	<brief_title>Topotecan Combination With Docetaxel Refractory and/or Advanced Solid Tumors</brief_title>
	<detailed_description>Upon determination eligibility , patient randomly assign one two treatment arm : For ever 2 patient treat , 1 receive treatment A ( Paclitaxel + Carboplatin + Gemcitabine ) 1 receive treatment B ( Gemcitabine + Vinorelbine ) . The study blind patient doctor know treatment assign . Upon determination eligibility , patient receive : - Docetaxel + Topotecan In order determine appropriate dose regimen progress future phase II trial , two different dose schedule Topotecan docetaxel utilize .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>To include study , must meet following criterion : Adult &gt; 18 year age ECOG performance status 0 1 Received 3 less chemotherapy regimen metastatic set Adequate bone marrow , liver kidney function Prior brain metastasis must inactive asymptomatic No previous treatment Topotecan docetaxel Understand nature study give write informed consent You participate study follow apply : Moderate severe peripheral neuropathy Active concurrent infection serious underlie medical condition Known HIV positivity Pregnant lactate Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>